Funding available for research on innovative drug and device treatments for mental disorders, substance use, and alcohol use, promoting collaboration between academia and industry through U01 mechanism.
Funding for collaborative research on new treatments for mental disorders, substance use disorders, and alcohol use disorder, emphasizing novel drugs/devices and industry-academic partnerships.
NIH supports exploratory, phased clinical research on the neurobiological mechanisms of substance use disorders, including relevant circuitry and behavior; clinical trials are optional.
This grant funds early stage trials of new drugs and neuromodulatory devices for psychiatric disorders, aiming to de-risk and attract further funding.
Supports preclinical and clinical research to develop interventions to prevent or treat substance use disorders and overdose, advancing candidates toward regulatory approval or clinical adoption.
Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.